# GO and hepatocellular carcinoma (HCC)

**URL:** <https://community.alliancegenome.org/t/go-and-hepatocellular-carcinoma-hcc/7632>\
**Category:** Paper Alert\
**Created:** [April 17, 2024, 11:35pm UTC](https://community.alliancegenome.org/t/go-and-hepatocellular-carcinoma-hcc/7632 "2024-04-17T23:35:02Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![suzi](https://community.alliancegenome.org/user_avatar/community.alliancegenome.org/suzi/32/606_2.png) [@suzi](https://community.alliancegenome.org/u/suzi)\
**Post date:** [April 17, 2024, 11:35pm UTC](https://community.alliancegenome.org/t/go-and-hepatocellular-carcinoma-hcc/7632/1 "2024-04-17T23:35:02Z")

</div>

Liver cancer is the third leading cause of cancer deaths, and most cases are hepatocellular carcinoma (HCC). HCC can be modeled in mice- and in a new Scientific Reports, Zhang et al. provide valuable proteomic data of this model. GO was used, alongside other tools, to highlight seven HCC prognostic markers that will help future research.

Read the full free article now: [**Proteomic analysis of DEN and CCl4-induced hepatocellular carcinoma mouse model**](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10997670/)

 ![Fig 3A from Zhang et al., Upregulation of actin cytoskeleton in DEN and CCl4-induced HCC mouse model.](https://community.alliancegenome.org/uploads/default/original/1X/97e54ee671784903518b779ce13734c3a3cb4ee1.jpeg)